#### **Supplementary Methods**

#### **Patient details and treatment**

Patients either had myeloablative conditioning (cyclophosphamide and fractinonated total body irradiation) or reduced intensity conditioning (fludarabine and melphalan) (Supplementary Table 1). All allogenic HSCT patients had prophylactic cyclosporin A and high-dose acyclovir (day -5 to day 28 or discharge) with subsequent valganciclovir (to day 100). Patients with high CMV DNAemia (all NIR patients except p47) were treated with ganciclovir (14 days) but only two patients p4 and p13 were on treatment (just finished) when the blood sample was taken.

#### **JARID2 and HDAC6 inhibition**

JARID2 and HDAC6 inhibition studies were performed on CD8+ T cells isolated from 40 ml blood from healthy donors using the RosetteSep™ Human CD8+ T Cell Enrichment Cocktail (StemCell Technology, Cambridge, UK). For JARID2 inhibition, cells were cultured with JIB-04 (46 nM or 1150 nM; Selleckchem, Houston, TX) for 4 h. For HDAC6 inhibition, cells were cultured with CAY10603 (20 nM, 500 nM, or 2500 nM; Selleckchem) for 2 h then stimulated with phorbol myristate acetate (PMA; 10 ng/mL, Sigma-Aldrich, St. Louis, MI) and ionomycin (1 nM, Sigma-Aldrich) for 2 h.

#### **Immunofluorescence microscopy**

Immunofluorescence microscopy was performed on cytospins prepared from FACS sorted, CMV-specific T cells. The cells were permeabilised with 1% Triton X-100 for 20 min and probed with mouse anti-JARID2 (ab93288, Abcam, Cambridge, UK), goat anti-HDAC6 (ab196351, Abcam), rabbit anti-KDM6B (ab169197, Abcam), mouse anti-PI3KCG, mouse anti-NFATC1 (sc-7294, Santa Cruz Biotechnology, Dallas, TX), or rabbit

anti-KLF16 (NMP2-30580 Novus Biologicals, Littleton, CO), followed by anti-mouse Alexa-Fluor-568 (A10037, Life Technologies), anti-goat Alexa-Fluor-633 (A20182, Life Technologies), or anti-rabbit Alexa-Fluor-488 (A21206, Life Technologies). Coverslips were mounted (ProLong Diamond Antifade Reagent, Life Technologies) and imaged by confocal laser scanning microscopy (Leica DMI8, x100 oil immersion lens). Total cytoplasmic (PI3KGC) or nuclear (all others) fluorescence intensity was measured (ImageJ, NIH, Bethesda, USA) in a minimum of 20 cells. The 20 plus cells were randomly selected on the DAPI only images to ensure integrity of the cells before quantification of the protein staining.

#### **Global chromatin accessibility**

FAIRE was carried out as previously described<sup>1</sup>. Briefly, cells were cross-linked with 1% formaldehyde and lysed. Chromatin-bound DNA was sheared by sonication, phenol-chloroform extracted, and purified with the Zymo-SpinTM I kit (Zymo Research, Irvine, CA). FAIRE DNA libraries and a mixed total input were prepared with the NEBNext<sup>®</sup> Ultra DNA Library Prep Kit for Illumina® (New England BioLabs, Ipswich, MA). FAIRE libraries were single-end 75bp sequenced on an Illumina NextSeq at the Ramaciotti Centre for Genomics. Samples from 4 IR (p01, p8, p15, and p37) and 4 NIR (p04, p14, p25, and p47) recipients were separately pooled.

#### **Flow cytometry**

To detect or isolate CMV-specific or naïve T cells, PBMCs were incubated with APC- or PE-conjugated MHC class I multimers specific for the HLA A\*01:01-restricted epitope VTEHDTLLY, HLA A\*02:01-restricted epitope NLVPMVATV, HLA B\*07:02-restricted

epitope ELKRKMIYM (Immudex, Copenhagen, Denmark). Cells were incubated with PerCP-Cy5.5-conjugated anti-CD8 (eBioscience; Thermo Fisher Scientific, Waltham, MA), Alexa-Fluor-700- or Pacific Blue-conjugated anti-CD4 (BD Biosciences; Thermo Fisher Scientific), live/dead near IR (Thermo Fisher Scientific), PE-Cy7 CCR7 (BD Bioscience), and CD45RA-FITC (BD Biosciences). To assess MHC-multimer frequencies, cells were acquired using a BD LSR Fortessa and data analysed in FlowJo (TreeStar). To isolate CMV-specific and naïve T cells (CD45RA+ CCR7+), cells were sorted using a FACS Aria-IIIu cell sorter (BD Biosciences).

#### **Gene expression analysis**

Gene expression was measured by single-end 75bp sequencing on a NextSeq500 at the Ramaciotti Centre for Genomics, University of New South Wales, Australia. RNA was isolated using the RNAeasy micro kit (Qiagen, CA). First-strand cDNA was synthesized from 1  $\mu$ g total RNA using the SuperScript<sup>TM</sup> III First-Strand Synthesis System (Invitrogen, Thermo Fisher Scientific), and  $qRT$ -PCR was carried out with gene-specific TaqMan probes on the Applied Biosystems ViiA 7 Real-Time PCR System (Life Technologies). RNA libraries were prepared from DNase-treated RNA using the SMARTer Total RNA-seq pico input (Clontech Laboratories; Mountain View, CA) and single-end 75bp sequenced on a NextSeq500 at the Ramaciotti Centre for Genomics, University of New South Wales, Australia.

#### **Bioinformatics analysis**

Sequences were adapter stripped (Trimmomatic-0.33), cleaned of ribosomal sequences (TagDust, RNAseq), and mapped to the Hg19 genome with Bowtie2 (2.2.5) (FAIRE-seq)<sup>2</sup> or Hisat2 (RNA-seq)<sup>3</sup>. RNA-seq gene expression was measured using HOMER

 $(pc3, -count exon)<sup>4</sup>$  and variance stabilization and differential expression were performed in DeSeq2<sup>5</sup> with a false discovery rate (FDR) of  $\leq$ 0.2. The less stringent FDR was chosen because considerable variation is expected in these human patient samples and the signatures were to be used for further comparison to epigenomic data which benefits from reduced false negative rates. DeSeq2 values incorporate the zero-centered normal prior and thus shrinkage is greater for the log2-fold change estimates from genes with low counts and high dispersion. Genes on ChrY or with low counts were discarded. Although it is worth noting that the number of reads mapped to ChrY from p14 (female donor to male patient), was as low as that from p01 (female donor to female patient), supporting the assertion that the profiled cells are derived from the transplanted donor cells.

For FAIRE-seq, duplicate (via Picard), multi-mapping reads were removed, and enriched regions were determined against a mixed total input sample using the broad option in MACS2<sup>6</sup> and filtered on q-values <0.01 and ≥3 fold enrichment. Specific peaks were those only detected in either IR or NIR and whose counts were at least 1.5 fold higher in one sample than the other. HOMER was used to create bedGraph files, annotate peaks, and find Gene Ontology (GO) and motif enrichment. CD8+ naïve and memory-annotated chromatin states were condensed from RoadMap data<sup>7</sup>. CLOVER (p<0.05) <sup>8</sup> was used to find motif enrichment using the JASPAR 2016 position weight matrices and background sequences with regions standardised to 500bp and matching GC content from HOMER. Genes were classified as epigenomic regulators according to EpiFactors<sup>9</sup> and transcription factors according to their 'Protein Function' in the Protein Atlas and grouped by InterPro domain (similar to previous publications<sup>10</sup>).

Enriched regions in publicly available ChIP-seq data were obtained from  $CISTROME<sup>11</sup>$ , with regions with the same factor and cell type concatenated to produce 1640 ChIP sets. Bedtools<sup>12</sup> was used to calculate the overlap with our region sets (after standardising to 500bp and liftOver to Hg38). ChIP sets that (1) overlapped less than 15% of the IR or NIR regions, or (2) had similar (<1.2-fold difference) occurrence in IR and NIR regions were discarded before creating the occurrence matrix. A score of 1 was given when an overlap was detected and 0 if not, and factor clustering was performed with Pearson distances and average linkage. JARID2 (iPSC, GSM1180134)<sup>13</sup> and HDAC6 (activated T cells, GSM393957)<sup>14</sup> ChIP-seq tracks were obtained via CISTROME and converted to Hg19 using CrossMap.

Enrichment in the ranked genelist from the RNA-seq data (normalised by library size in DeSeq2, unlogged) was calculated by geneset enrichment analysis (GSEA; Signal2Noise, weighted, nominal p-values <0.05, FDR <0.35)<sup>15</sup>. Rank metrics and normalised enrichment scores (NES) for our genesets in specific GEO datasets were also calculated by GSEA (Signal2Noise, weighted).

Ggplot2, cluster, and factoextra were used for visualization, similarity calculations, PCA and other clustering. String<sup>16</sup> was used to create functional association networks that were visualised in Cytoscape<sup>17</sup> with molecular function classified primarily by 'Protein Function' in the Protein Atlas<sup>18</sup>.

#### **References**

1. Simon JM, Giresi PG, Davis IJ, Lieb JD. A detailed protocol for formaldehyde-assisted isolation of regulatory elements (FAIRE). *Curr Protoc Mol Biol*. 2013;Chapter 21:Unit21 26.

- 2. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*. 2012;9(4):357-359.
- 3. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. *Nat Meth*. 2015;12(4):357-360.
- 4. Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell*. 2010;38(4):576-589
- 5. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology*. 2014;15(12):550.
- 6. Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol*. 2008;9(9):R137.
- 7. Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH Roadmap Epigenomics Mapping Consortium. *Nat Biotechnol*. 2010;28(10):1045-1048.
- 8. Frith MC, Fu Y, Yu L, Chen JF, Hansen U, Weng Z. Detection of functional DNA motifs via statistical over-representation. *Nucleic Acids Res*. 2004;32(4):1372-1381.
- 9. Medvedeva YA, Lennartsson A, Ehsani R, et al. EpiFactors: a comprehensive database of human epigenetic factors and complexes. *Database (Oxford)*. 2015;2015:bav067.
- 10. Jolma A, Yan J, Whitington T, et al. DNA-binding specificities of human transcription factors. *Cell*. 2013;152(1-2):327-339.
- 11. Liu T, Ortiz JA, Taing L, et al. Cistrome: an integrative platform for transcriptional regulation studies. *Genome Biology*. 2011;12(8):R83.
- 12. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010;26.
- 13. Kaneko S, Bonasio R, Saldana-Meyer R, et al. Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. *Mol Cell*. 2014;53(2):290-300.
- 14. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. *Cell*. 2009;138(5):1019-1031.
- 15. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences*. 2005;102(43):15545-15550.
- 16. Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: qualitycontrolled protein-protein association networks, made broadly accessible. *Nucleic Acids Res*. 2017;45(D1):D362-d368.
- 17. Shannon P, Markiel A, Ozier O, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. *Genome Research*. 2003;13(11):2498-2504.
- 18. Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. *Nat Biotechnol*. 2010;28(12):1248-1250



**A**

**B**



 $-03$ 

 $\begin{array}{ccc}\n\text{Enrichment s} \\
\text{Enrichment s} \\
\text{S} & \text{S} \\
\text{S} & \text{S}\n\end{array}$ 

**THE REAL PROPERTY** 



 $-0.25$   $-0.30$   $-0.35$   $-0.40$   $-0.45$ 

<u> Hillian Maria</u>

**Figure S1** 

**p = 0.02 NES = -1.5 FDR= 0.07**

**TILLIT** 



**Figure S1** 



### **Figure S1**

## **Supplementary Figure 1: Identification and characterisation of gene signatures associated with reactive and non-reactive CMV+ lymphocytes.**

(A) Similarities in transcriptome profiles of CMV-specific memory CD8+ lymphocytes from patients undergoing HSCT were assessed using Pearson correlations. Non-reactive (NIR) patients in green and red and reactive (IR) patients in blue. (B) GSEA and ranking of genes from more in NIR to more in IR reveals enrichment of genesets at either ends of the scale. (C) Genes differentially expressed in lymphocytes from IR and NIR recipients using false discovery rate (FDR) 0.2 cut-off and ranked according to their response in peak CMV infection (GSE12589). Z-score scaled. Expression assessed by rank metric (weighted Signal2Noise). Normalised enrichment score shown. \* p-value < 0.05. (D-E) Expression of transcription factors (D) and chromatin modulators (E) in reactive and non-reactive cells. Sized by significance, where larger = more significant. Values incorporate zero-centred normal priors and thus shrinkage is greater for the log2-fold change estimates from genes with low counts and high dispersion.





**Sup Figure 2** 









**I**



## **Supplementary Figure 2: Identification and characterisation of chromatin accessibility in reactive and non-reactive CMV+ lymphocytes.**

(A) Similarities between the accessibility profiles of CMV-specific memory CD8+ T cells from patients undergoing HSCT and normal naïve CD8+ were assessed using Pearson correlations (B) The groups of regions with differential chromatin accessibility (CA) can be further subgrouped by their CA in naïve cells (C) The distances from the transcriptional start site of genes with higher expression in cells from NIR or IR recipients, to the nearest accessible region. Median shown in red. (D) Factors from ChIP-seq experiments in CISTROME were clustered by whether they bound (red) or not (white) in the IR<sup>+</sup>NIR<sup>-</sup> or IR<sup>-</sup>NIR<sup>+</sup> accessible regions. Several regions near differentially expressed genes are named. Chromatin state in memory cells CD8+ is shown on left (see **Figure 4F**), colours below show motif family. (E) Transcription factor and chromatin modifier binding in the IR<sup>+</sup>NIR<sup>-</sup> and IR<sup>-</sup>NIR<sup>+</sup> accessible regions as assessed by the proportion bound in publicly available ChIP-seq data from CISTROME and enrichment of JASPAR binding motifs. Motif enrichment measured by Clover Enrichment Score, against regions with similar GC content. (F) The proportion IR<sup>+</sup>NIR<sup>-</sup> and IR<sup>-</sup>NIR<sup>+</sup> accessible regions that are within 50 kb of differentially expressed genes that are bound by DNA-binding proteins from the CISTROME ChIPseq datasets. (G) Enrichment of motifs in IR<sup>+</sup>NIR<sup>-</sup> and IR<sup>-</sup>NIR<sup>+</sup> accessible regions that are within 50 kb of differentially expressed genes. (H) Factor binding and enrichment of motifs in naïve-IR+NIR+ regions that are within 50 kb of differentially expressed genes. (I) Protein levels and localisation of NFATC1 and KLF16 in reactive and non-reactive lymphocytes. Total nuclear (TNFI) or cytoplasmic (TCFI) florescence intensity were measured in a minimum of n = 20 cells for 2 different donors. DAPI shows nucleus. \*\*\*\* p < 0.0001 Scale bar is 5µm. (E-H) X is CTCF binding. (G) All significant (p < 0.05) motifs plotted. Enrichment measured by Clover Enrichment Score.



### **Sup Figure 3**

# **Supplementary Figure 3: Schematic of the regulation of accessibility in immune reactive (IR) and non-immune reactive (NIR) CMV lymphocytes.**

Gene regulation in memory lymphocytes derived from hematopoietic stem cell transplants and responding to CMV infection with different efficiencies. Receptors (trapezoids), kinases (diamonds), transcription factors (triangles), and chromatin remodellers (stars) that are more highly expressed in reactive (blue) or non-reactive (green) cells give rise to chromatin with differential accessibility. In some cases, this contributes to differences in gene expression (dark italics), while in others it may prime genes (light italics) for expression upon receipt of additional signals.